Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27978333 | 1.00 | KMT2A (0.48) | KMT2AMEN1MAPK1HDAC4HDAC1 | |
| SCHEMBL15535916 | 1.00 | KMT2A (0.48) | KMT2AMEN1MAPK1HDAC4HDAC1 | |
| SCHEMBL30170170 | 0.94 | KMT2A (0.41) | KMT2AMEN1MAPK1HDAC4HDAC1 | |
| SCHEMBL18631592 | 0.94 | KMT2A (0.41) | KMT2AMEN1MAPK1HDAC4HDAC1 | |
| SCHEMBL24815908 | 0.86 | KMT2A (0.39) | KMT2AMEN1MAPK1HDAC4HDAC1 | |
| SCHEMBL2110140 | 0.86 | KMT2A (0.39) | KMT2AMEN1MAPK1HDAC4HDAC1 | |
| SCHEMBL2549745 | 0.86 | KMT2A (0.39) | KMT2AMEN1MAPK1HDAC4HDAC1 | |
| SCHEMBL27218008 | 0.86 | KMT2A (0.39) | KMT2AMEN1MAPK1HDAC4HDAC1 | |
| SCHEMBL8271718 | 0.86 | KMT2A (0.39) | KMT2AMEN1MAPK1HDAC4HDAC1 | |
| SCHEMBL27218038 | 0.86 | KMT2A (0.39) | KMT2AMEN1MAPK1HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025090919-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | PITON THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025090920-A1 | COMPOSITIONS AND METHODS FOR TREATING DYSFUNCTION OF GLUCOSE METABOLISM AND/OR REGULATION | PITON THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| CN-117098544-A | Diterpenoid compounds acting on Protein Kinase C (PKC) | K-GEN治疗股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4209494-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | Fujian Akeylink Biotechnology Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2019-07-11 | — | — | US | disclosed |
| EP-2995615-A1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014118612-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES OF SYNTHESIS OF SAXAGLIPTIN AND NOVEL COMPOUNDS | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2014-08-07 | — | — | WO | disclosed |
| WO-2013175395-A2 | IMPROVED PROCESS FOR PREPARATION OF SAXAGLIPTIN AND ITS SALTS | DR. REDDYS LABORATORIES LIMITED (IN) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013111158-A2 | PROCESS FOR THE PREPARATION OF DPP-IV INHIBITOR | MSN LABORATORIES LIMITED (IN) | 2013-08-01 | — | — | WO | disclosed |
| US-RE44186-E1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2272825-A2 | N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1553937-B1 | GLYCINENITRILE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | BRISTOL MYERS SQUIBB CO (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2005012249-A2 | ADAMANTYGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004037181-A2 | GLYCINENITRILE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | KMT2A 1719/4885MEN1 2512/4885MAPK1 1154/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | KMT2A 3963/4885MEN1 3338/4885MAPK1 1034/4885 |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | VIP, PREP, PRAP1 | KMT2A 3623/4885MEN1 1707/4885MAPK1 998/4885 |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | KMT2A 1488/4885MEN1 2401/4885MAPK1 1172/4885 |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCB, PRKCI | KMT2A 3236/4885MEN1 4010/4885MAPK1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.